This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Medifast (MED) Queued for Q2 Earnings: Things to Consider
by Zacks Equity Research
Medifast's (MED) second-quarter 2023 performance will likely reflect challenges related to customer acquisition and higher cost inflation.
New Strong Sell Stocks for June 26th
by Zacks Equity Research
ARCH, CSUAY and MED have been added to the Zacks Rank #5 (Strong Sell) List on June 26, 2023.
Medifast (MED) Down 8.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Medifast (MED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medifast's (MED) Q1 Earnings Top Estimates, Sales Decline Y/Y
by Zacks Equity Research
Medifast's (MED) first-quarter 2023 results reflect lower sales on reduced Coach productivity and cost inflation. While earnings increase year over year.
Factors to Consider Ahead of Medifast's (MED) Q1 Earnings
by Zacks Equity Research
Medifast's (MED) first-quarter performance is likely to reflect the adverse impacts of macroeconomic volatility and increased inflation.
Medifast (MED) Down 2.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Medifast (MED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medifast (MED) Stock Down Despite Q4 Earnings, Sales Beat
by Zacks Equity Research
Medifast's (MED) fourth-quarter 2022 results reflect reduced Coach productivity and cost inflation. While earnings increase year over year, revenues dip
Medifast (MED) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Medifast (MED) delivered earnings and revenue surprises of 69.72% and 9.96%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Medifast (MED) Readies for Q4 Earnings: Everything to Note
by Zacks Equity Research
Medifast's (MED) fourth-quarter results are likely to reflect the adverse impacts of increased cost inflation, while strength in the OPTAVIA lifestyle solution and coaching support system bodes well.
Post Holdings (POST) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Post Holdings (POST) delivered earnings and revenue surprises of 86.21% and 5.65%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Medifast (MED) Banks on OPTAVIA Strength Amid Cost Woes
by Zacks Equity Research
Medifast (MED) benefits from its OPTAVIA lifestyle solution and coaching support system. However, the gross margin has been declining year over year for a while now.
International Flavors (IFF) Q3 Earnings & Sales Top Estimates
by Zacks Equity Research
International Flavors' (IFF) Q3 top line beats estimates but came in line with last year. The company lowered the 2022 sales guidance citing foreign currency impact and a challenging operating environment.
Is Darling Ingredients (DAR) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Hershey (HSY) Beats on Q3 Earnings & Sales, Raises 2022 View
by Zacks Equity Research
Hershey's (HSY) third-quarter 2022 results reflect higher earnings and sales on growth across all segments. Management raises 2022 guidance.
Medifast (MED) Cuts View Despite Q3 Earnings Beat, Stock Down
by Zacks Equity Research
Medifast's (MED) third-quarter 2022 results reflect reduced Coach productivity and cost inflation. Management curtails guidance.
Medifast's (MED) Q3 Earnings Upcoming: Things Worth Noting
by Zacks Equity Research
Medifast's (MED) third-quarter 2022 results are likely to reflect cost-related challenges, whereas strength in the OPTAVIA lifestyle solution and coaching support system bodes well.
Church & Dwight (CHD) Q3 Earnings Beat Mark, Sales Rise Y/Y
by Zacks Equity Research
Church & Dwight's (CHD) third-quarter 2022 results reflect increased sales on growth in Consumer Domestic and Specialty Products units. However, earnings decline year over year.
Why Is Medifast (MED) Down 19.8% Since Last Earnings Report?
by Zacks Equity Research
Medifast (MED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medifast (MED) Down More Than 20% in 3 Months on Cost Woes
by Zacks Equity Research
Medifast (MED) has been seeing high SG&A expenses and escalated raw material costs. The company expects short-term margin pressure in 2022 due to inflation and continued investments.
Are Options Traders Betting on a Big Move in Medifast (MED) Stock?
by Zacks Equity Research
Investors need to pay close attention to Medifast (MED) stock based on the movements in the options market lately.
Medifast (MED) Q2 Earnings Top Estimates, Guidance Lowered
by Zacks Equity Research
Medifast's (MED) second-quarter 2022 results reflect increased active earning OPTAVIA Coaches and elevated costs. Management cuts guidance for 2022 due to inflation.
Medifast (MED) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Medifast (MED) delivered earnings and revenue surprises of 17.99% and 2%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights include UFP Industries, MEDIFAST, Skyline, Hudson Global and Expeditors International of Washington
by Zacks Equity Research
UFP Industries, MEDIFAST, Skyline, Hudson Global and Expeditors International of Washington are part of Zacks Screen of the Week article.
Medifast (MED) Readies for Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Medifast's (MED) second-quarter 2022 results are likely to reflect gains from its OPTAVIA lifestyle solution and coaching support system, while escalated costs might have been a concern.
Explore DuPont Analysis & Pick 5 Top Stocks
by Sanghamitra Saha
Do you have more faith in DuPont analysis than simple ROE calculation? Tap UFP Industries (UFPI), MEDIFAST (MED), Skyline (SKY), Hudson Global (HSON) and Expeditors International of Washington (EXPD).